WordNet

lack of success; "he felt that his entire life had been a failure"; "that year there was a crop failure"
loss of ability to function normally; "kidney failure"
an act that fails; "his failure to pass the test"
an unexpected omission; "he resented my failure to return his call"; "the mechanics failure to check the brakes"
a person with a record of failing; someone who loses consistently (同)loser, nonstarter, unsuccessful person
an event that does not accomplish its intended purpose; "the surprise party was a complete failure"
incapable of being reversed; "irreversible momentum toward revolution"

PrepTutorEJDIC

〈U〉(…における)『失敗』,不成功《+『in』+『名』(do『ing』)》 / 〈C〉失敗者,落後者;失敗した企て,不できなもの / 〈U〉〈C〉怠慢,不履行 / 〈U〉〈C〉(…の)不足,欠乏《+『of』+『名』》 / 〈U〉〈C〉(…の)破産《+『of』+『名』》 / 〈U〉(…の)『衰弱』,減退《+『in』(『of』+『名』》
逆にできない,裏返しできない / (決定などが)取り消しできない,変更できない
腎臓の

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 急性腎障害（急性腎不全）または慢性腎臓病患者に対する診断的アプローチ diagnostic approach to the patient with acute kidney injury acute renal failure or chronic kidney disease
2. 新生児における急性腎障害（急性腎不全） acute kidney injury acute renal failure in the newborn
3. 小児における慢性腎臓病のマネージメントの概要 overview of the management of chronic kidney disease in children
4. 成人における慢性腎臓病マネージメントの概要 overview of the management of chronic kidney disease in adults
5. 化学療法関連腎毒性および腎不全患者における用量調整 chemotherapy related nephrotoxicity and dose modification in patients with renal insufficiency

English Journal

Depleted TGF-β1 levels in end stage renal disease patients from North India.

Kumar A1, Gupta V2, Chaudhary M3, Singh A4, Sehajpal PK5.Author information 1Department of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab 143005, India; International Centre for Genetic Engineering and Biotechnology, New Delhi, India. Electronic address: akumar@icgeb.res.in.2Department of Biotechnology, DAV College, Amritsar, Punjab, India. Electronic address: bio_vic@yahoo.com.3Department of Nephrology, Kidney Hospital, Jalandhar, Punjab, India. Electronic address: drm_chaudhary@yahoo.co.in.4Subsidiary Medical Center, Chawinda Kalan, Amritsar, Punjab, India. Electronic address: avrs_02@yahoo.com.5Department of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, Punjab 143005, India. Electronic address: sehajpalpk@yahoo.com.AbstractEnd stage renal disease is a clinical state that extends from chronic renal failure and is marked by an irreversible loss of renal function. TGF-β1 mediated renal fibrosis is a common pathology implicated in this form of kidney disease. In this study circulating protein and mRNA levels of TGF-β1 cytokine were investigated among ESRD patients and respective controls from North India. Physician diagnosed 192 ESRD patients, on hemodialysis, and 130 normal controls participated in the present study. TGF-β1 circulating levels were measured by ELISA and its expression was quantified using competitive-PCR. Mean TGF-β1 protein levels were 2.7-fold lower in ESRD patients as compared to normal controls (p<0.001). Additionally, TGF-β1 mRNA transcripts of this cytokine were also significantly lower in the diseased population compared to controls (p<0.001). These results imply that TGF-β1 has not played its anticipated pro-fibrotic role and anti-inflammatory function in the studied population.
Gene.Gene.2014 Jan 25;534(2):440-3. doi: 10.1016/j.gene.2013.09.116. Epub 2013 Oct 7.
End stage renal disease is a clinical state that extends from chronic renal failure and is marked by an irreversible loss of renal function. TGF-β1 mediated renal fibrosis is a common pathology implicated in this form of kidney disease. In this study circulating protein and mRNA levels of TGF-β1 c
PMID 24113078

Neurologic aspects of multiple organ transplantation.

Zivković SA.Author information Neurology Service, Department of Veterans Affairs and Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: zivkovics@upmc.edu.AbstractComplex multiorgan failure may require simultaneous transplantation of several organs, including heart-lung, kidney-pancreas, or multivisceral transplantation. Solid organ transplantation can also be combined with hematopoietic stem cell transplantation to modulate immunologic response to a solid organ allograft. Combined multiorgan transplantation may offer a lower rate of allograft rejection and lower immunosuppression needs. In recent years, intestinal and multivisceral transplantations became viable as a rescue treatment for patients with irreversible intestinal failure who can no longer tolerate total parenteral nutrition with 70% survival after 5 years which is comparable to other types of solid organ allografts. Post-transplant neurologic complications were reported in up to 86% of allograft recipients and greatly overlap in intestinal and multivisceral allograft recipients, without a significant effect on the outcome of transplantation. Other common organ combinations in multiorgan transplantation include kidney-pancreas, which is mostly used for patients with renal failure and uncontrolled diabetes, and heart-lung for patients with congenital heart disease and idiopathic pulmonary arterial hypertension. Kidney-pancreas transplantation frequently results in an improvement of diabetic complications, including diabetic neuropathy. Heart-lung allograft recipients have very similar clinical course and spectrum of neurologic complications to lung transplant recipients. At this time there are no reports of an increased risk of graft-versus-host disease with combined transplantation of solid organ allograft and hematopoietic stem cells. Chronic immunosuppression and complex toxic-metabolic disturbances after multiorgan transplantation create a permissive environment for development of a wide spectrum of neurologic complications which largely resemble complications after transplantations of individual components of complex multiorgan allografts.
Handbook of clinical neurology.Handb Clin Neurol.2014;121:1305-17. doi: 10.1016/B978-0-7020-4088-7.00089-4.
Complex multiorgan failure may require simultaneous transplantation of several organs, including heart-lung, kidney-pancreas, or multivisceral transplantation. Solid organ transplantation can also be combined with hematopoietic stem cell transplantation to modulate immunologic response to a solid or
PMID 24365421

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene.

Román-Ortiz E, Mendizabal Oteiza S, Pinto S, López-Trascasa M, Sánchez-Corral P, Rodríguez de Cordoba S.Author information Pediatric Nephrology Unit, Hospital La Fe, Bulevar sur s/n, 46026, Valencia, Spain, eroman@comv.es.AbstractBACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. Outcomes of kidney transplantation are poor owing to aHUS recurrence and loss of graft. Patients carrying CFH mutations or CFH/CFHR1 hybrid genes present a very high risk of recurrence despite preventive plasmapheresis. Evaluation of recent data suggests that prophylactic eculizumab pretransplant might be the preferred therapy if available.
Pediatric nephrology (Berlin, Germany).Pediatr Nephrol.2014 Jan;29(1):149-53. doi: 10.1007/s00467-013-2591-8. Epub 2013 Aug 24.
BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. Outcomes of kidney transplantation are poor owing to aHUS recurrence and loss of graft. Patients carrying CFH mutations or CFH/CFHR1 hybrid genes pres
PMID 23982707